AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 241 min read$VSTM

Calkins Daniel sold $424 of VSTM

Calkins Daniel (Chief Financial Officer) sold 55 shares of Verastem, Inc. (VSTM) at $7.70 on 2026-09-21 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Calkins Daniel
Published Sep 24, 2026, 12:10 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 24, 2026, 12:44 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$VSTM
Neutral
high confidence
Mentioned
$VSTM
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VSTMNeutralLow
01

Why it matters

The transaction is a standard liquidity event with minimal market impact.

02

Market read

Low relevance; typical insider sell with no material effect on stock price.

03

What to watch

Potential upcoming financing or strategic moves not disclosed.

Relevance 2/10Novelty 4/10Timing: filed Sep 23, 2026

Background

Form 4 filings disclose insider transactions; this is a routine 10b5‑1 sale by Verastem's CFO.

Company-level read

Ticker impact

$VSTMNeutralHigh confidence
Context

CFO Daniel Calkins sold 55 shares for $423.50 via a 10b5‑1 plan on Sep 21, 2026.

Expected impact

No significant impact expected.

Evidence & confidence

Sale size is trivial relative to holdings and market cap; typical pre‑arranged sale.

Market effects

Sector

None; insider sale does not affect biotech sector outlook.

Regional

None; limited to Verastem shareholders.

Global

None

Counterpoint

What could challenge this read

Even small insider sales can signal confidence issues; monitor for further disposals.

Key entities

  • Company
    Verastem, Inc.

    Biotech firm listed on Nasdaq (VSTM).

  • Executive
    Daniel Calkins

    Chief Financial Officer of Verastem.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

VSTM insider trading history →

Related articles

OCT 28
$NVCRLowAI 8/10

Novocure partners with Verastem on pancreatic cancer trial

Novocure (NVCR) and Verastem Oncology (VSTM) partner to test Tumor Treating Fields therapy with VS-7375 for pancreatic cancer. Trial to start in 2027, focusing on safety and tolerability in 25 patients. Novocure will fund and manage the trial, while Verastem supplies the drug. The treatment aims to combine chemotherapy, VS-7375, and Tumor Treating Fields. Pancreatic cancer has a low survival rate and limited treatment options.

investing.com2 min
OCT 28
$NVCRLowAI 8/10

A planned trial will test electric-field therapy with chemotherapy and an experimental drug.

Novocure (NVCR) and Verastem Oncology plan a clinical trial to evaluate Tumor Treating Fields (TTFields) therapy with chemotherapy and Verastem’s experimental drug VS-7375 for locally advanced pancreatic cancer. The trial, expected to start in 2027, will assess safety and preliminary efficacy in about 25 patients. Novocure will manage and fund the trial, while Verastem will supply the drug. Both companies believe the combination could offer a new treatment approach for this challenging cancer.

stocktitan.net2 min
OCT 16
$VSTMHighAI 8/10

Wainwright reiterates Verastem stock rating on China trial data

H.C. Wainwright reiterated a Buy rating and $18.00 price target for Verastem (VSTM) after positive clinical trial data from China. The stock rose 10% last week to $9.23, up 46% in six months. GenFleet's data showed promising results for GFH375, the same molecule as Verastem's VS-7375, in colorectal and pancreatic cancer trials. Analysts maintain a strong buy consensus with targets ranging from $12 to $24.

investing.com2 min